Praxis Precision Medicines vs TG Therapeutics
Praxis Precision Medicines (PRAX), health care, and TG Therapeutics (TGTX), health care, side by side on market value, valuation, margins, balance sheet and price change. Higher and lower are marked; neither is called better.
TG Therapeutics is worth $9.5B on the stock market and Praxis Precision Medicines $8.5B: TG Therapeutics is valued at 11% more. Over the past year Praxis Precision Medicines's share price has moved +68.5% and TG Therapeutics's +101%.
Key facts
- Praxis Precision Medicines market value
- $8.5B
- TG Therapeutics market value
- $9.5B
- TG Therapeutics P/E
- 93.6
- Praxis Precision Medicines revenue
- $0FY to 2025-12-31
- TG Therapeutics revenue
- $616.3MFY to 2025-12-31
- Superinvestors holding both
- 0
Market values as of .
| Measure | Praxis Precision Medicines | TG Therapeutics |
|---|---|---|
| Sector | Health Care | Health Care |
| Country | ||
| Fiscal year ends | 2025-12-31 | 2025-12-31 |
| Size | ||
| Market cap | $8.5Blower | $9.5Bhigher |
| Revenue | $0lower | $616.3Mhigher |
| Earnings | -$303.3Mlower | $447.2Mhigher |
| Employees | 168lower | 399higher |
| Total assets | $937.9Mlower | $1.1Bhigher |
| Valuation | ||
| P/E | — | 93.6 |
| P/S | — | 15.4 |
| P/B | 6.8lower | 15.4higher |
| Dividend yield | 0.00% | 0.00% |
| Profitability | ||
| Operating margin | — | 20.0% |
| Balance sheet | ||
| Net assets | $878.1Mhigher | $648Mlower |
| Total liabilities | $59.8Mlower | $415.2Mhigher |
| Total debt | — | $245.6M |
| Cash on hand | $357.3Mhigher | $79.1Mlower |
| Price change | ||
| Today | -1.68%lower | -0.08%higher |
| 1 year | +68.5%lower | +101%higher |
Market value, P/E, P/B, dividend yield and price changes are from live quotes (Yahoo Finance; prices may be delayed 15 minutes or more). Revenue, earnings, operating margin and the balance-sheet figures are from each company's latest annual report filed with the SEC (collected 2026-11-12); a company that reports in another currency is converted to US dollars at the exchange rate of that day. P/S sets today's market value against the latest fiscal year's revenue. “Higher” and “lower” compare the two numbers only; a higher P/E or more debt is not better. Dividend yield and P/B are shown only for companies based in the US. A dash means no figure is on file.
Which superinvestors hold them
From each tracked investor's latest 13F filing. A 13F lists long positions in US-listed shares at a quarter end, filed up to 45 days later.
Both (0)
None of the tracked investors.
Praxis Precision Medicines only (2)
TG Therapeutics only (0)
None of the tracked investors.
Percentages are each holding's share of that investor's reported portfolio. Who owns PRAX
More on Praxis Precision Medicines
Further comparisons
Praxis Precision Medicines against its closest peers
TG Therapeutics against its closest peers
Learn
Questions and answers
Which is bigger, Praxis Precision Medicines or TG Therapeutics?
By market value, TG Therapeutics is the larger: $9.5B against $8.5B for Praxis Precision Medicines. By revenue in its latest fiscal year, TG Therapeutics is the larger: $616.3M against $0 for Praxis Precision Medicines.
Which has the higher dividend yield?
Neither: both stand at 0.00%. Dividend yield is the last twelve months' dividends as a share of today's share price.
Which superinvestors own both Praxis Precision Medicines and TG Therapeutics?
None of the tracked superinvestors holds both in their latest 13F filing. 2 hold Praxis Precision Medicines and 0 hold TG Therapeutics.
Cite this page
Funkfolio, “Praxis Precision Medicines vs TG Therapeutics”, data as of 18 November 2026. https://funkfolio.com/compare/prax-vs-tgtx
Underlying data: Yahoo Finance quotes; SEC annual reports collected 2026-11-12; 13F filings.